Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ILMN · Nasdaq · United States · Laboratory Analytical Instruments
In shortILLUMINA, INC. is profitable, generates cash and holds more cash than debt, with revenue stable (−0.7% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 18.6% | 79/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 19.6% | 98/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 33.4% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 15.0% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.08× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.55× | 81/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 7.99× | 62/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 3.04 | 50/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 21.4% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.10× | 99/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 18.3% | 43/100 |
| Operating margin volatility | 41.2% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -1.8% | 7/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 4,526 | 4,584 | 4,504 | 4,372 | 4,343 |
| Cost of revenue | 1,372 | 1,612 | 1,760 | 1,511 | 1,473 |
| Gross profit | 3,154 | 2,972 | 2,744 | 2,861 | 2,870 |
| Research & development | 1,185 | 1,321 | 1,354 | 1,169 | 967 |
| Selling, general & admin | 2,092 | 1,297 | 1,612 | 1,092 | 1,086 |
| Operating income | (123) | (4,179) | (1,069) | (833) | 807 |
| Interest expense | 61 | 26 | 77 | 100 | 101 |
| Pre-tax income | 884 | (4,336) | (1,117) | (1,179) | 1,086 |
| Income tax | 122 | 68 | 44 | 44 | 236 |
| Net income | 762 | (4,404) | (1,161) | (1,223) | 850 |
| Diluted EPS | $5.04 | −$28.00 | −$7.34 | −$7.69 | $5.45 |
| Diluted shares (millions) | 151 | 157 | 158 | 159 | 156 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
3.04 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 28, 2026 · Data updated Jul 31, 2026